Millie
your market intelligence analyst
Search Results
24 results
Your search is now limited to «Excipients» expert search.
Kukmin Ilbo (Korea) 08/11/2020 05:14
종근당은 복약편의성이 개선된 치주질환 치료제 ‘이튼큐 플러스’를 출시했다. 이튼큐 플러스는 옥수수불검화정량추출물 단일제제인 이튼큐에 후박추출물을 추가한 생약 성분의 복합제다. 주성분인 옥수수불검화정량추출물은 치주인대의 재생을 도와 치아가 흔들리는 것을 막고 치조골을 재건시켜 잇몸 속 기초를 튼튼하게 하는데 도움을 준다. 후박추출물은 치주질환의 원인균에 대한 항균효과와 항염효과가 우수해 잇몸 염증에 대한 저항력을 강화시켜준다. 또 이튼큐 플러스는 장기 복용에도 부작용이 없는 생약 성분 치료제로 안전성이 입증됐다. 종근당이 독자 개발한 정제 축소기술 iLET(Innovative Low Excipient Tablet) 특허공법을 적용해 현재 출시되어 있는 동일성분 제품 중 정제 사이즈를 가장 작게 줄임으로써 다수의 약물을 함께 복용하는 중·장년층 환자의 복약편의성을 개선한 것이 특징이다. 종근당 관계자는 “치주질환 치료제는 장기 복용하는 환자가 많고 용법·용량에 맞춰 복용하는 복약순응도가 치료에 큰 영향을 미친다”라며 “복약편의성을 개선하고 안전성이 입증된 이튼큐 플러스가 치주질환 치료에 큰 도움을 줄 것”이라고 말했다. 조민규 쿠키뉴스 기자.
Seeking Alpha 08/09/2020 23:56
Surmodics, Inc. (NASDAQ:SRDX) Q3 2020 Earnings Conference Call August 5, 2020 17:00 ET Company Participants Tim Arens - Vice President, Finance & Chief Financial Officer Gary Maharaj - Chief Executive Officer Conference Call Participants Jim Sidoti - Sidoti & Company Brooks O'Neil - Lake Street Capital Markets David Saxon - Needham & Company Presentation Operator Good day, and welcome to the Surmodics Third Quarter Fiscal 2020 Earnings Conference Call.
Seeking Alpha 08/09/2020 05:32
Kezar Life Sciences, Inc. (NASDAQ:KZR) Q2 2020 Earnings Conference Call August 5, 2020 16:30 ET Company Participants Celia Economides - Senior Vice President of Strategy & External Affairs John Fowler - Chief Executive Officer Noreen Henig - Chief Medical Officer Christopher Kirk - President & Chief Scientific Officer Marc Belsky - Chief Financial Officer Conference Call Participants Blair Cohen - H.C.
Business Wire 08/07/2020 08:00
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that the United States Food and Drug Administration (FDA) has approved Lampit® (nifurtimox) for use in pediatric patients (from birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi (T. cruzi).1 Lampit, an antiprotozoal medication will be available in a new, dividable tablet that can be split on the scored lines by hand.1-3 According to pre.
MAHs shall also ensure that active substances and excipients used in their FPs are manufactured in compliance with good manufacturing practices in line with Article 46(f) of Directive 2001/83/EC.
FeedNavigator (EU) 08/06/2020 06:04
Bile acids have recently been studied for potential applications as formulation excipients and enhancers for drug release; however, some bile acids are not suitable for this application. Unconjugated lithocholic acid (ULCA) has recently shown drug formulation-stabilizing and anti-inflammatory effect …

Automotive Industries

Business Issues

Companies - Public

Companies - Venture Funded

Global Markets

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Market Research Topics

Political Entities

Sources

Strategic Scenarios

Trends